Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Laurent Olivier Mosnier · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $443,750 — Project Summary This application seeks to improve basic understanding of the molecular mechanisms that mediate cytoprotective actions of coagulation proteases on cells and will test novel approaches for the potential treatment of thrombo- inflammatory disease. Despite recent advances, major gaps in …
Catalin Filipeanu · LSU HEALTH SCIENCES CENTER · 2021 · $600,541 — With prevalence as high as 55% for individuals aged 55 and older in United States, hypertension is a major risk factor contributing to cardiovascular diseases (CVD) and global mortality, hence remaining an increasingly important medical and public health issue. The role of the renin-angiotensin syst…
Noam A Cohen · PHILADELPHIA VA MEDICAL CENTER · 2021 — ABSTRACT Severe acute respiratory syndrome coronavirus SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19) has led to a pandemic with a mortality of approximately 3.5% and a wide range of morbidity outcomes negatively impacted by pre-existing conditions. Given the prevalence of p…
Yagna Jarajapu · NORTH DAKOTA STATE UNIVERSITY · 2021 · $253,750 — Targeting Mas Receptor for Diabetic Vascular Disease in Older Adults Abstract Prevalence of diabetes is high among older adults and is expected to rise, and diabetes increases risk for cardiovascular disease. Accumulated evidence suggests that bone marrow-derived progenitor cells maintain vascular h…
Florian Douam · BOSTON UNIVERSITY MEDICAL CAMPUS · 2021 · $242,950 — Project Summary We are in the midst of an unprecedented, modern pandemic as a result of the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. SARS-CoV-2 is one of three known coronaviruses that can replicate in the lower respiratory tract and cause pneumoni…
DAVID G BESSELSEN · UNIVERSITY OF ARIZONA · 2021 · $306,997 — ABSTRACT The pandemic COronaVIrus disease 2019 (COVID-19) is an infectious disease, which is caused by a novel and highly pathogenic virus strain SARS-CoV-2 (Severe acute respiratory virus syndrome coronavirus 2). The infection may cause severe lower respiratory tract infection with acute respirator…
KATHLEEN E. RODGERS · UNIVERSITY OF ARIZONA · 2021 · $1,531,012 — PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide, and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. In rece…
Susan P Travers · OHIO STATE UNIVERSITY · 2021 · $305,085 — The goals of this Emergency Competitive Revision are to develop (Aim 1) and deploy (Aim 2) a novel, objective, psychophysical smell and taste screening test to detect the onset of COVID 19 in at-risk populations. Complementary to the temperature screening procedures currently in use, this tool is pr…
Yufen CHEN · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $439,694 — This investigation will use state-of-the-art, quantitative Magnetic Resonance Imaging to determine whether SARS-CoV-2 has effects on the brain that can be detected at one month and at 6 months following mild to moderate COVID. Blood brain barrier integrity, cerebral blood flow, cerebrovascular injur…
RICHARD J SMEYNE · THOMAS JEFFERSON UNIVERSITY · 2021 · $429,000 — ABSTRACT Approximately16.5 million people have been infected with the SARS-CoV2 virus with approximately 650,000 (and rising) deaths. While primarily a respiratory virus, clinical observations appear to demonstrate nervous system involvement. These include those associated with the CNS (headache, c…
Qizhi Gong · UNIVERSITY OF CALIFORNIA AT DAVIS · 2021 · $235,500 — PROJECT SUMMARY A sudden onset of olfactory impairment is reported as one of the early clinical manifestations of COVID-19, particularly among mild and asymptomatic patients. Though reports indicate that olfactory loss resolves within two weeks, it is unknown what proportion of the patients develops…
Vaithilingaraja Arumugaswami · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $3,636,473 — Project Summary/Abstract SARS-CoV-2 primarily affects the respiratory system but extra-pulmonary manifestations in individuals with COVID-19 are commonly seen. All major organ systems have been reported to be affected by SARS-CoV-2 and complications arising from ensuing organ dysfunction significant…
Sumant Singh Chugh · RUSH UNIVERSITY MEDICAL CENTER · 2021 · $562,646 — Abstract The COVID 19 pandemic has been associated with the development of proteinuria in up to 40% of hospitalized patients. This cardinal manifestation of kidney disease is most likely related to effects of the extensive cytokine storm in these patients on glomeruli, the filtering units of the kid…
Matthew J. Flick · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 · $580,295 — SUMMARY Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; CoV2) is the first highly pathogenic and highly transmissible human coronavirus that is the causative agent for the worldwide COVID-19 pandemic. As of November 2020, 50 million cases of CoV2 infection worldwide and 1.25 million dea…
Takako Araki · UNIVERSITY OF MINNESOTA · 2021 · $421,625 — PROJECT SUMMARY COVID-19–related extra-pulmonary damage is common and may even be observed in patients with mild COVID- 19 symptoms. There is an urgent and immediate need to establish optimal post-infection health care strategies for these patients, yet mechanisms underlying their appearance remain …
Cathleen M Lutz · JACKSON LABORATORY · 2021 · $491,863 — Abstract To date, most of the research using mouse models for COVID-19 has been done using a transgenic mouse model expressing high levels of the human ACE2gene driven by the Keratin-18(K18) promoter. While this model has been extremely useful, it has some notable limitations: disease progression is…
Eric D Lazartigues · UNIVERSITY OF NORTH DAKOTA · 2021 · $642,597 — COVID-19 is a US and global disaster which has led to the deaths of almost a million individuals, including over 203,000 Americans, thus far. COVID-19 is caused by a novel beta-coronavirus (CoV) known as Severe Acute Respiratory Syndrome (SARS)-CoV-2, which was reported to cause severe pneumonia and…
Lothar Hennighausen · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $337,442 — Objective 1 During this reporting period the Laboratory of Genetics and Physiology has made major progress in deciphering and understanding molecular mechanisms underlying hormone-controlled genetic programs in the mammary gland (PMID: 33854063). Enhancers are transcription component platforms that…
William C Knowler · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $140,115 — This project, in part, represents an extension of work previously reported as Project Numbers Z01 DK69037, Z01 DK069097 and Z01 DK069000. It also reports on continuation of work previously reported under Project Numbers DK069036-23, DK069063-17, and DK069100-06. All work related to diabetic kidney d…
Eric D Lazartigues · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $3,672,336 — COVID-19 is a US and global disaster which has led to the deaths of almost a million individuals, including over 203,000 Americans, thus far. COVID-19 is caused by a novel beta-coronavirus (CoV) known as Severe Acute Respiratory Syndrome (SARS)-CoV-2, which was reported to cause severe pneumonia and…